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ABSTRACT 
Lung cancer causes 1.4 million deaths annually. In the search for functional foods as 
complementary therapies against lung cancer, the immuno-stimulatory properties of the 
vegetable Morinda citrifolia leaves were investigated and compared with the anti-cancer drug 
erlotinib. Lung tumour-induced BALB/c mice were fed with 150 mg kg−1 or 300 mg kg−1 
body weight of the leaf extract, or erlotinib (50 mg kg−1 body-weight) for 21 days. The 300 
mg kg−1 body weight extract significantly (and dose-dependently) suppressed lung tumour 
growth; the extract worked more effectively than the 50 mg kg−1 body weight erlotinib 
treatment. The extract significantly increased blood lymphocyte counts, and spleen tissue B 
cells, T cells and natural killer cells, and reduced the epidermal growth factor receptor 
(EGFR) which is a lung adenocarcinoma biomarker. The extract also suppressed the 
cyclooxygenase 2 (COX2) inflammatory markers, and enhanced the tumour suppressor gene 
(phosphatase and tensin homolog, PTEN). It inhibited tumour growth cellular gene 
(transformed mouse 3T3 cell double minute 2 (MDM2), V-raf-leukemia viral oncogene 1 
(RAF1), and mechanistic target of rapamycin (MTOR)) mRNA expression in the tumours. 
The extract is rich in scopoletin and epicatechin, which are the main phenolic compounds. 
The 300 mg kg−1Morinda citrifolia leaf 50% ethanolic extract showed promising potential as 
a complementary therapeutic dietary supplement which was more effective than the 50 mg 
kg−1 erlotinib in suppressing lung adenocarcinoma. Part of the mechanisms involved 
enhancing immune responses, suppressing proliferation and interfering with various tumour 
growth signalling pathways. 
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